Tina Cascone, MD
Enriched profileAssociate Professor with Tenure; Multidisciplinary Section Chief and Director of Translational Research, Department of Thoracic/Head and Neck Medical Oncology · The University of Texas MD Anderson Cancer Center
Tina Cascone is Associate Professor with Tenure; Multidisciplinary Section Chief and Director of Translational Research, Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 450 publications with 13,617 citations (h-index 56); ClinicalTrials.gov lists 5 registered studies with this person as an investigator.
Data verified 16 Oct 2026
Overview
Updated 18 Oct 2026
Tina Cascone, MD, PHD, is Associate Professor with Tenure at The University of Texas MD Anderson Cancer Center, Houston, TX. The public record shows 450 publications with 13,617 citations (h-index 56), centered on Lung Cancer (NSCLC/SCLC). It also documents an investigator role on 5 registered clinical trials, industry payments reported by 13 companies, 2 NIH-funded awards (2021–2026).
- Most recent indexed publication: 2026 · Journal for immunotherapy of cancer
- Top research focus: Lung Cancer (NSCLC/SCLC)
- 5 registered trials on ClinicalTrials.gov
- Open Payments reporting from 13 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 34 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Sponsor: AstraZeneca
- Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer
Sponsor: M.D. Anderson Cancer Center
- Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer
Sponsor: M.D. Anderson Cancer Center
Industry payments
Updated 18 Oct 2026
13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20259 payments
- E.R. Squibb & Sons, L.L.C.Program year20257 payments
- AstraZeneca UK LimitedProgram year20254 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
69.8%Kinase inhibitor69.8%Tagrisso80%Lorbrena21%Part D<11 patientsMetabolism & gastrointestinal
12.6%Serotonin-3 Receptor Antagonist12.6%Ondansetron Hcl100%Part D≥15 patientsBlood & clotting
8.8%Factor Xa inhibitor8.8%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
2 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:
- Dissecting the role of B lineage cells in mediating response of resectable lung cancer to neoadjuvant immune-based therapy
University of Tx Md Anderson Can Ctr
FY2026$677,143R01CA287734 - Dissecting the role of B lineage cells in mediating response of resectable lung cancer to neoadjuvant immune-based therapy
University of Tx Md Anderson Can Ctr
FY2025$670,358R01CA287734 - Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer
University of Tx Md Anderson Can Ctr
FY2025$606,797R01CA262425
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Unbiased avidity-based isolation of antigen-specific T cells.
Journal for immunotherapy of cancer
Article2026 - Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.
Nature reviews. Clinical oncology
Review2026
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/tina-cascone-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Tina-Cascone-39926965
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- LinkedIn
es.linkedin.com/posts/gecp_los-doctores-tina-cascone-y-william-n-activity-7271491319871516672-ClMu
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →es.linkedin.com ↗ - LinkedIn
linkedin.com/posts/society-for-immunotherapy-of-cancer-sitc_discover-more-about-2025-sitc-at-large-director-activity-7325534831524626435-CZU1
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - Other
sitcancer.org/membership/2025-sitc-election/cascone
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sitcancer.org ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
- Ph.D.
Medical and Surgical Oncology and Clinical Immunology, University of Campania Luigi Vanvitelli, Naples, Italy
2012verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- Principal Investigator
NEOSTAR, NeoCOAST, NeoCOAST-2, and CheckMate-77T clinical trials of neoadjuvant/perioperative immunotherapy in operable NSCLC
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →newswise.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →the-asci.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →the-asci.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →the-asci.org ↗
Secondary affiliations
appointments beyond the home institution- Regular Faculty Member
Immunology Program, UT MD Anderson Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - Regular Faculty Member
Cancer Biology Program, UT MD Anderson Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - Regular Member
MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences (Cancer Biology and Immunology graduate programs)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gsbs.uth.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iaslc.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →goodpods.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →facebook.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →targetedonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center